EB 病毒 (EBV) 是一种致癌病毒，与多种恶性肿瘤相关，包括经典霍奇金淋巴瘤 (cHL)。尽管已知其相关性，但在 cHL 中，针对 EBV 的体液免疫反应的具体作用仍知之甚少。为了解决这个问题，我们进行了一项研究，使用定制的蛋白质微阵列来测量 cHL 患者的抗体反应，并匹配从东亚医院病例对照研究中招募的健康对照。我们鉴定出 16 种 EBV 阳性 cHL 中的 IgG 抗体与对照相比显着升高，定义了“EBV 阳性 cHL 的东亚抗体特征”。我们利用之前来自英国、丹麦和瑞典的欧洲 cHL 病例对照研究的数据，评估了不同欧洲人群对这 16 种抗体的反应。来自“EBV 阳性 cHL 的东亚抗体特征”的抗体子集（14/16，87.5%）与欧洲人群中的 cHL 显着相关。相反，我们评估了之前研究中在东亚人群中发现的“EBV 阳性 cHL 欧洲抗体特征”，其中包括 18 种 EBV 抗体（2 种 IgA，16 种 IgG）。这些抗体的一个子集（15/18，83.3%）与东亚人群中的 cHL 保持显着相关性。这种抗体特征的交叉比较强调了 EBV 抗体在人群中的强大普遍性。在两种人群特异性抗体特征中发现的五种抗 EBV IgG 抗体（LMP-1、TK、BALF2​​、BDLF3 和 BBLF1）代表“EBV 阳性 cHL 的核心特征”。我们的研究结果表明，针对这些核心 EBV 蛋白的抗体反应反映了特定的 EBV 基因表达模式，可作为 EBV 阳性 cHL 的潜在生物标志物，与人群特定因素无关。© 2024 作者。约翰·威利出版的《国际癌症杂志》

Epstein-Barr virus (EBV) is an oncogenic virus associated with various malignancies, including classical Hodgkin lymphoma (cHL). Despite its known association, the specific role of humoral immune response to EBV remains poorly characterized in cHL. To address this, we conducted a study using a custom protein microarray to measure the antibody responses in cHL patients and matched healthy controls recruited from an East-Asian hospital-based case-control study. We identified 16 IgG antibodies significantly elevated in EBV-positive cHL compared with controls, defining an "East-Asian antibody signature of EBV-positive cHL." We evaluated responses against these 16 antibodies in a distinct European population, leveraging data from our previous European cHL case-control study from the UK, Denmark, and Sweden. A subset of antibodies (14/16, 87.5%) from the "East-Asian antibody signature of EBV-positive cHL" exhibited significant associations with cHL in the European population. Conversely, we assessed the "European antibody signature of EBV-positive cHL" identified in our prior study which consisted of 18 EBV antibodies (2 IgA, 16 IgG), in the East-Asian population. A subset of these antibodies (15/18, 83.3%) maintained significant associations with cHL in the East-Asian population. This cross-comparison of antibody signatures underscores the robust generalizability of EBV antibodies across populations. Five anti-EBV IgG antibodies (LMP-1, TK, BALF2, BDLF3, and BBLF1), found in both population-specific antibody signatures, represent a "core signature of EBV-positive cHL." Our findings suggest that the antibody responses targeting these core EBV proteins reflect a specific EBV gene expression pattern, serving as potential biomarkers for EBV-positive cHL independent of population-specific factors.© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.